Pipeline Watch: Phase III Readouts In Atopic Dermatitis, Ischemic Stroke
Executive Summary
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
You may also be interested in...
Cell And Gene Therapy Manufacturing: Catalent Snaps Up MaSTherCell
Consolidation and acquisitions among contract manufacturers of cell and gene therapies is a growing trend, as Catalent acquires Belgium- and US-based MaSTherCell Global for $315m, and other cell and gene therapy manufacturers address capacity shortages.
United Therapeutics' Unituxin Disappoints In SCLC
Targeting gangliosides expressed on SCLC tumors has been explored by United Therapeutics in the Phase II/III DISTINCT study, but top-line results show no effect on overall survival.
Atopic Dermatitis: Ruxolitinib And Baricitinib Spearheading New Therapies
Top-line Phase III results from Incyte’s TruE-AD2 study of ruxolitinib cream and Eli Lilly’s BREEZE-AD4 and BREEZE-AD5 studies of oral baricitinib show that the compounds achieved primary endpoints in atopic dermatitis, and they may eventually challenge Sanofi’s Dupixent’s growth in the sector.
Need a specific report? 1000+ reports available
Buy Reports